Showing 371-380 of 3970 results for "".
CBD in the Holistic Practice of Dermatology
https://practicaldermatology.com/topics/psoriasis/cbd-in-the-holistic-practice-of-dermatology/23319/A growing body evidence suggests CBD may help with common symptoms of dermatologic diseases. Here’s what we know so far.Rising Skin Cancer Rates are a Global Reality
https://practicaldermatology.com/topics/general-topics/PD1009_04-php/20367/One group of researchers questions the skin cancer epidemic, but the overwhelming evidence suggests that rates are rising.Complications of Biologic Therapy for Psoriasis: Part II
https://practicaldermatology.com/topics/psoriasis/complications-of-biologic-therapy-for-psoriasis-part-ii/22039/Therapeutic success requires clinicians to understand emerging and established safety concerns.Moisturizers for Skin Diseases: New Insights
https://practicaldermatology.com/topics/atopic-dermatitis/moisturizers-for-skin-diseases-new-insights/22977/Exploring Patient-Reported Outcomes Measures in Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/exploring-patient-reported-outcomes-measures-in-atopic-dermatitis/23886/Patient-reported outcomes may solve some of the challenges with measuring the physical and psychosocial manifestations.Drug-Induced Dermatomyositis
https://practicaldermatology.com/topics/atopic-dermatitis/drug-induced-dermatomyositis/23357/It’s common practice to screen for underlying malignancy in dermatomyositis, but it is also important to look for drug-induced disease.Barrier Repair: Where Do We Stand?
https://practicaldermatology.com/topics/general-topics/barrier-repair-where-do-we-stand/21455/An update on skin moisturization and the use of prescription barrier repair agents for atopic dermatitis.Investigational Oral Treatments for Psoriasis: A Review of Phase 2 and 3 Trials
https://practicaldermatology.com/topics/psoriasis/investigational-oral-treatments-for-psoriasis-a-review-of-phase-2-and-3-trials/23318/Although biologic medications have proven to be highly effective in the treatment of psoriasis, there remains a need for oral medications that offer similar success rates. Here’s a look in the pipeline.Continuity of Psoriasis Care in the Era of COVID-19
https://practicaldermatology.com/columns/clinical-focus-1/continuity-of-psoriasis-care-in-the-era-of-covid-19/23285/While there’s no data about susceptibility to COVID-19 in psoriasis, there is relevant information on infectious complications from biologics.Psoriasis and the Metabolic Syndrome
https://practicaldermatology.com/topics/psoriasis/psoriasis-and-the-metabolic-syndrome/21535/Growing data support the notion that TNF inhibitors may decrease various risk factors for the metabolic syndrome.